Pretargeted Radioimmunotherapy in Cancer: An Overview

  • Stefano Papi
  • Chiara Grana Grana
  • Mirco Bartolomei
  • Laura Ravasi
  • Marta Cremonesi
  • Mahila Ferrari
  • Luigi Martano
  • Lucia Garaboldi
  • Marco Chinol
  • Giovanni Paganelli
Chapter
First Online:
Part of the Methods of Cancer Diagnosis, Therapy and Prognosis book series (HAYAT, volume 7)

Abstract

The concept of tumour targeting began at the turn of the twentieth century when Ehrlich (1907) postulated the idea of the “Magic Bullet” to target abnormal cells selectively on the basis of antigenic differences between normal and abnormal cells. No clinical application of this concept took place until Pressman and Keighley (1948) utilized labeled antibodies for cancer detection. Pressman et al. (1957) showed that monoclonal antibodies (MoAbs) labeled with radioactive iodine could be used in animals on a diagnostic basis. Later, Bale et al. (1960) demonstrated that tumour localizing antibodies could be used as a therapeutic agent for treating experimental neoplasms by means of the radioactivity. The modern era of targeted cancer therapy did not start until 1975, upon the publication of Kohler and Milstein’s (1975) work describing the technology for the production of MoAbs, also referred to as the “hybridoma technology”. This method allowed the production of a large amount of different MoAbs with high specificity towards tumour-associated antigens and opened the door to the preclinical and clinical research in the targeted radiotherapy of cancer using MoAbs, referred to as radioimmunotherapy (RIT).

Keywords

Anaplastic Astrocytoma Linear Energy Transfer Relative Biologic Effectiveness Radionuclide Therapy Bispecific Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Bale WF, Spar IL, and Goodland RL (1960) Experi-mental radiation therapy of tumor with I-131-carrying.antibodies to fibrin. Cancer Res 20: 1488Google Scholar
  2. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, Kvols LK, Krenning EP, Jamar F, and Pauwels S (2005) Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 46:99S-106SPubMedGoogle Scholar
  3. Boerman OC, van Schaijk FG, Oyen WJG, and Corstens FHM (2003) Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 44:400-411PubMedGoogle Scholar
  4. Caliceti P, Chinol M, Roldo M, Veronese FM, Semenzato A, Salmaso S, and Paganelli G (2002) Poly(ethylene glycol)-avidin bioconjugates: suitable candidates for tumor pretargeting. J Control Release 83:97-108PubMedCrossRefGoogle Scholar
  5. Cassady JR (1995) Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys 31:1249-1256PubMedCrossRefGoogle Scholar
  6. Chinol M, Grana C, Gennari R, Cremonesi M, Geraghty JG, and Paganelli G (2000) Pretargeted radiommunotherapy of cancer. In: Abrams PG, Fritzberg, AR, Radioimmunotherapy of Cancer. Marcel Dekker, New York, pp. 223-243Google Scholar
  7. Cremonesi M, Ferrari M, Chinol M, Stabin MG, Grana C, Prisco G, Robertson C, Tosi G, and Paganelli G (1999) Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med 26:110-120PubMedCrossRefGoogle Scholar
  8. Ehrlich P (1907) On immunity. With special reference to the relationship between distribution and action of antigens. J Royal Inst Publ Health 15:321-340Google Scholar
  9. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, and Wesson M (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109-122PubMedCrossRefGoogle Scholar
  10. Goldenberg DM, and Sharkey RM (2006) Advances in cancer therapy with radiolabeled mono­clonal antibodies. Q J Nucl Med Mol Imaging 50:248-264PubMedGoogle Scholar
  11. Goldenberg DM, and Sharkey RM (2007) Novel radiolabeled antibody conjugates. Oncogene 26:3734-3744PubMedCrossRefGoogle Scholar
  12. Goldenberg DM, Sharkey RM, Karacay H, McBride W, Hansen HJ, Chang CH, Rossi EA, Chatal JF, and Barbet J (2003) Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? (against). Eur J Nucl Med Mol Imaging 30:776-780Google Scholar
  13. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, and Chatal JF (2006) Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 24:823-834PubMedCrossRefGoogle Scholar
  14. Goodwin DA, and Meares CF (2001) Advances in pretargeting biotechnology. Biotechnol Adv 19:435-450PubMedCrossRefGoogle Scholar
  15. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, and Paganelli G (2002) Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: A pilot study. Br J Cancer 86:207-212PubMedCrossRefGoogle Scholar
  16. Karacay H, Sharkey RM, McBride WJ, Griffiths GL, Qu Z, Chang K, Hansen HJ, Goldenberg DM (2002) Pretargeting for cancer radioimmuno­therapy with bispecific antibodies: role of the bispecific antibody’s valency for the tumor target antigen. Bioconjug Chem 13:1054-1070PubMedCrossRefGoogle Scholar
  17. Kohler G, and Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497PubMedCrossRefGoogle Scholar
  18. Lehtolainen P, Taskinen A, Laukkanen J, Airenne KJ, Heino S, Lappalainen M, Ojala K, Marjomäki V, Martin JF, Kulomaa MS, and Ylä-Herttuala S (2002) Cloning and characterization of scavidin, a fusion protein for the targeted delivery of biotinylated molecules. J Biol Chem 227:8545-8550CrossRefGoogle Scholar
  19. Lubic SP, Goodwin DA, Meares CF, Song C, Osen M, and Hays M (2001) Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma. J Nucl Med 42:670-678PubMedGoogle Scholar
  20. Mann BD, Cohen MB, Saxton RE, Morton DL, Benedict WF, Korn EL, Spolter L, Graham LS, Chang CC, and Burk MW (1984) Imaging of human tumor xenografts in nude mice with radiolabeled monoclonal antibodies. Limitations of specificity due to nonspecific uptake of antibody. Cancer 54:1318PubMedCrossRefGoogle Scholar
  21. Paganelli G (2003) Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? (for). Eur J Nucl Med Mol Imaging 30:773-776PubMedCrossRefGoogle Scholar
  22. Paganelli G, Bartolomei M, Ferrari M, Cremonesi M, Broggi G, Maira G, Sturiale C, Grana C, Prisco G, Gatti M, Caliceti P, and Chinol M (2001) Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 16:227-235PubMedCrossRefGoogle Scholar
  23. Paganelli G, Belloni C, Magnani P, Zito F, Pasini A, Sassi I, Meroni M, Mariani M, Vignali M, Siccardi AG, and Fazio F (1992) Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur J Nucl Med 19:322-329PubMedCrossRefGoogle Scholar
  24. Paganelli G, Chinol M, Maggiolo M, Sidoli A, Corti A, Baroni S, and Siccardi AG (1997) The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy. Eur J Nucl Med 24:350-351PubMedCrossRefGoogle Scholar
  25. Paganelli G, Ferrari M, Cremonesi M, De Cicco C, Galimberti V, Luini A, Veronesi P, Fiorenza M, Carminati P, Zanna C, Orecchia R, and Veronesi U (2007) IART®: intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation. Breast 16:17-26PubMedCrossRefGoogle Scholar
  26. Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F, Robertson C, Zurrida S, Casadio C, Zoboli S, Siccardi AG, and Veronesi U (1999) Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 26:348-357PubMedCrossRefGoogle Scholar
  27. Paganelli G, Malcovati M, and Fazio F (1991) Monoclonal antibody pretargetting techniques for tumour localization: the avidin-biotin system. International workshop on techniques for amplification of tumour targetting. Nucl Med Commun 12:211-34PubMedCrossRefGoogle Scholar
  28. Pressman D, and Keighley G (1948) The zone of activity of antibodies as determined by the use of radioactive tracers; the zone of activity of nephritoxic antikidney serum. J Immunol 59:141-146PubMedGoogle Scholar
  29. Pressman D, Day ED, and Blau M (1957) The use of paired labelling in the determination of tumor localizing antibodies. Cancer Res 17:845PubMedGoogle Scholar
  30. Reardon DT, Meares CF, Goodwin DA, McTigue M, David GS, Stone MR, Leung JP, Bartholomew RM, and Frincke JM (1985) Antibodies to metal chelates. Nature 316:265-268CrossRefGoogle Scholar
  31. Sabatino G, Chinol M, Paganelli G, Papi S, Chelli M, Leone G, Papini AM, De Luca A, and Ginanneschi M (2003) A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors. J Med Chem 46:3170-3173PubMedCrossRefGoogle Scholar
  32. Sharkey RM, Hajjar G, Yeldell D, Brenner A, Burton J, Rubin A, and Goldenberg DM (2005) A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 46:620-633PubMedGoogle Scholar
  33. Strand SE, Zanzonico P, and Johnson TK (1993) Pharmacokinetic modeling. Med Phys 20:515PubMedCrossRefGoogle Scholar
  34. Urbano N, Papi S, Ginanneschi M, De Santis R, Pace S, Lindstedt R, Ferrari L, Choi SJ, Paganelli G, and Chinol M (2007) Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT®). Eur J Nucl Med Mol Imaging 34:68-77PubMedCrossRefGoogle Scholar
  35. Waldmann T (2003) ABCs of radioisotopes used for radioimmunotherapy: α- and β-emitters. Leuk Lymphoma 44:S107-S113PubMedCrossRefGoogle Scholar
  36. Wilbur DS, Hamlin DK, Chyan MK, Kegley BB, and Pathare PM (2001) Biotin reagents for antibody pretargeting. 5. Additional studies of biotin conjugate design to provide biotinidase stability. Bioconjug Chem 12:616-623PubMedCrossRefGoogle Scholar
  37. Wilbur DS, Hamlin DK, and Chyan MK (2006) Biotin reagents for antibody pretargeting. 7. Inves­tigation of chemically inert biotinidase blocking functionalities for synthetic utility. Bioconjug Chem 17:1514-1522PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Stefano Papi
    • 1
  • Chiara Grana Grana
    • 1
  • Mirco Bartolomei
    • 1
  • Laura Ravasi
    • 1
  • Marta Cremonesi
    • 2
  • Mahila Ferrari
    • 2
  • Luigi Martano
    • 1
  • Lucia Garaboldi
    • 1
  • Marco Chinol
    • 1
  • Giovanni Paganelli
    • 1
  1. 1.Division of Nuclear MedicineEuropean Institute of OncologyMilanItaly
  2. 2.Division of Health PhysicsEuropean Institute of OncologyMilanItaly

Personalised recommendations